Recombinant Human L1CAM Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 777-NC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
777-NC-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

CAA42508

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all L1CAM Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human L1CAM protein
Human L1CAM
(Ile20-Glu1120) & (Arg864‑Glu1120)
Accession # CAA42508		 IEGRMD Human IgG1
(Pro100-Lys330)		 6-His tag
N-terminus C-terminus

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ile20 & Arg864

Predicted Molecular Mass

150.4 kDa (monomer) & 55.9 kDa (truncated)

SDS-PAGE

210-225 kDa, reducing conditions

Activity

Measured by the ability of the immobilized protein to support the adhesion of Neuro-2A mouse neuroblastoma cells.
When 5 x 104 cells/well are added to Recombinant Human L1CAM Fc Chimera coated plates (25 µg/mL with 100 µL/well), >30% will adhere for 1 hour incubation at 37 °C.
Optimal dilutions should be determined by each laboratory for each application.

Reviewed Applications

Read 1 review rated 5 using 777-NC in the following applications:

Formulation, Preparation and Storage

777-NC
Formulation Lyophilized from a 0.2 μm filtered solution in Tris-Citrate and NaCl.
Reconstitution
Reconstitute at 200 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 4 weeks, -20 to -70 °C under sterile conditions after reconstitution.

Background: L1CAM

L1CAM (Neural cell adhesion molecule L1, also known as L1, CD171 and NCAM-L1) is a founding member of the L1 family, Immunoglobulin (Ig) superfamily of molecules (1-4). It was initially described as a 200-230 kDa neural adhesion molecule that likely played a key role in mouse nervous system development (4-6). Subsequent studies have confirmed the adhesive nature of the molecule, and expanded its activities in both neural and nonneural cell types. L1 is now recognized to play a key role in cell migration, adhesion, neurite outgrowth, myelination and neuronal differentiation (1, 7, 8). It does so through a series of cis and trans interactions that involve multiple copartners and target receptors (1, 3, 6, 8). Cells known to express L1 are varied, and include immature oligodendrocytes (9), CD4+ T cells, B cells and monocytes (10), both motor and sensory Schwann cells (11, 12), intestinal epithelial progenitor cells (12), cerebellar granule and Purkinje cells (5, 13, 14), and multiple tumor cells such as melanoma (15) plus pancreatic duct and lung carcinoma cells (16, 17). Human L1 was first identified as a 215 kDa glycoprotein on the surface of SKNAS neuroblastoma cells (18). Subsequent cloning established its precursor as being 1257 amino acids (aa) in length (19, 20). The molecule is a type I transmembrane (TM) protein that contains an 1101 aa extracellular region (aa 20-1120) plus a 114 aa cytoplasmic domain (aa 1144-1257). The extracellular region possesses six C2-type Ig-like domains (aa 35-607) followed by five fibronectin (FN) type III domains (aa 612-1108). As noted, L1 participates in multiple cis and trans interactions, and some of these interaction sites have been mapped to select Ig or FN domains. For instance, Ig-like domains #1, 2 and 6 associate with NP-1, L1 (homotypic binding), and various integrins, respectively (21‑23). The latter interaction is mediated by one (in human) or two (in mouse) RGD motifs (23, 24). Other molecules that heterotypically associate with L1 include NCAM, neurocan, CD24 and EGFR. The cytoplasmic tail contains no kinase motifs, but does possess a FIGQY peptide that interacts with ankyrin, and an RSLE sequence that mediates clathrin-associated endocytosis (1). There are two splice variants, one each in the intracellular and extracellular domains.  A deletion of RSLE adversely affects endocytosis, while a Leu substitution for aa 26-31 interfers with numerous heterotypic interactions (25, 26).  In general, the full-length L1 molecule is a neuron-associated isoform. L1 is known to undergo proteolysis, either by plasmin or ADAMs. This generates soluble isoforms of varying sizes (140-200 kDa) that retain bioactivity, and which can be incorporated into the surrounding ECM (5, 13, 27-30). The membrane fragments (30-80 kDa) undergo further processing, most importantly by gamma-secretase, to generate a soluble 28 kDa intracellular domain. This domain is SUMOylated, and believed to possess an NLS at Lys1147.  Upon presumed entry into the nucleus, L1 is posited to activate L1-responsive genes. Human and mouse L1 precursors share 88% aa sequence identity.

References

  1. Maness, P.F. and M. Schachner (2007) Nat. Neurosci. 10:19.
  2. Wei, C.H. and S.E. Ryu (2012) Exp. Mol. Med. 44:413.
  3. Faspel, J. and M. Grumet (2003) Front. Biosci. 8:1210.
  4. Herron, L.R. et al. (2009) Biochem. J. 419:519.
  5. Rathjen, F.G. and M. Schachner (1984) EMBO. J. 3:1.
  6. Keifel, H. et al. (2011) Trends Mol. Med. 17:178.
  7. Dihne, M. et al. (2003) J. Neurosci. 23:6638.
  8. Kadmon, G. et al. (1998) Dev. Immunol. 6:205.
  9. Itoh, K. et al. (2000) J. Neurosci. Res. 60:579.
  10. Jouet, M. et al. (1995) Mol. Brain Res. 30:378.
  11. He, Q. et al. (2012) Neurosci. Lett. 521:57.
  12. Thor, G. et al. (1987) EMBO J. 6:2581.
  13. Sadoul, K. et al. (1988) J. Neurochem. 50:510.
  14. Hubbe, M. et al. (1993) Eur. J. Immunol. 23:2927.
  15. Hoja-Lukowicz, D. et al. (2012) Glycoconj J. Apr 29. [Epub ahead of print].
  16. Geismann, C. et al. (2009) Cancer Res. 69:4517.
  17. Tischler, V. et al. (2011) Mol. Cancer 10:127.
  18. Mujoo, K. et al. (1986) J. Biol. Chem. 261:10299.
  19. Kobayashi, M. et al. (1991) Biochim. Biophys. Acta 1090:238.
  20. Hlavin, M.L. and V. Lemmon (1991) Genomics 11:416.
  21. Castellani, V. et al. (2002) EMBO J. 21:6348.
  22. Zhao, X. and C-H Siu (1995) J. Biol. Chem. 270:29413.
  23. Oleszewski, M. et al. (1999) J. Biol. Chem. 274:24602.
  24. Felding-Habermann, B. et al. (1997) J. Cell Biol. 139:1567.
  25. Kamiguchi, H. et al. (1998) J. Neurosci. 18:5311.
  26. De Angelis, E. et al. (2001) J. Biol. Chem. 276:32738.
  27. Montgomery, A.M.P. et al. (1996) J. Cell Biol. 132:475.
  28. Sadoul, R. et al. (1989) J. Neurochem. 53:1471.
  29. Reidle, S. et al. (2009) Biochem. J. 420:391.
  30. Lutz, D. et al. (2012) J. Biol. Chem. 287:17161.

Long Name

Cell Adhesion Molecule L1

Alternate Names

CAML1, CD171, HSAS, HSAS1, MASA, MIC5, NCAM-L1, S10, SPG1

Entrez Gene IDs

3897 (Human); 16728 (Mouse); 50687 (Rat)

Gene Symbol

L1CAM

UniProt

CAA42508

Additional L1CAM Products

Product Documents for Recombinant Human L1CAM Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human L1CAM Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.